Arena Pharma (ARNA) Misses Q4 EPS by 28c

Arena Pharma (NASDAQ: ARNA) reported Q4 EPS of ($2.54), $0.28 worse than the analyst estimate of ($2.26). Revenue for the quarter came in at $54 thousand versus the consensus estimate of $660 thousand.

Cash, cash equivalents and marketable securities were $0.7 billion at December 31, 2021 as compared to $1.1 billion at December 31, 2020

For earnings history and earnings-related data on Arena Pharma (ARNA) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance
• Stratasys (SSYS) Tops Q2 EPS by 2c ;; Offers Guidance